Responses
Extended report
Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
Compose a Response to This Article
Other responses
No responses have been published for this article.